Acerus Pharmaceuticals (OTCMKTS:ASPCF) Trading Down 6.3%

Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF) shares fell 6.3% on Friday . The company traded as low as $0.05 and last traded at $0.05, 100 shares were traded during mid-day trading. A decline of 99% from the average session volume of 7,887 shares. The stock had previously closed at $0.05.

The company has a quick ratio of 2.72, a current ratio of 2.94 and a debt-to-equity ratio of 0.70. The business’s 50-day moving average price is $0.04 and its 200-day moving average price is $0.04.

Acerus Pharmaceuticals (OTCMKTS:ASPCF) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $0.15 million for the quarter.

About Acerus Pharmaceuticals (OTCMKTS:ASPCF)

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.

Recommended Story: What is the balance sheet?

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.